Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 18/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2871237 | 0.99 | CCR1 (0.64) | CCR1CYP2C19KCNH2KDM4ERECQL | |
| SCHEMBL13184058 | 0.87 | CCR1 (0.50) | CCR1CYP2C19KCNH2 | |
| SCHEMBL13682566 | 0.85 | CCR1 (0.69) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4449970 | 0.84 | CCR1 (0.61) | CCR1CYP2C19KCNH2 | |
| SCHEMBL13024341 | 0.83 | L3MBTL1 (0.53) | CCR1 | |
| SCHEMBL4816268 | 0.82 | CCR1 (0.56) | CCR1CYP2C19KCNH2KDM4ERECQL | |
| SCHEMBL2876859 | 0.81 | CCR1 (0.64) | CCR1CYP2C19KCNH2 | |
| SCHEMBL14542886 | 0.80 | CCR1 (0.47) | CCR1CYP2C19KCNH2 | |
| SCHEMBL2866903 | 0.79 | CCR1 (1.00) | CCR1CYP2C19KCNH2 | |
| SCHEMBL2867193 | 0.79 | CCR1 (0.74) | CCR1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-7842693-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261987-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | CCR1 1/4885CYP2C19 4206/4885KCNH2 3836/4885 |
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885CYP2C19 4206/4885KCNH2 3836/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885CYP2C19 4113/4885KCNH2 4441/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885CYP2C19 4113/4885KCNH2 4441/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885CYP2C19 4206/4885KCNH2 3836/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | CCR1 1/4885CYP2C19 4113/4885KCNH2 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.